Vaccine News and Research

Latest Vaccine News and Research

CWRU researchers receive NIAID grant to conduct HIV research and clinical trials

AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

23 Jan 2014

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

NPS MedicineWise urges parents to ensure that children's vaccinations are up to date

Following a recent spate of measles cases being reported in a number of Australian states, NPS MedicineWise is reminding parents to check whether their children’s immunisations are up to date before they head back to school next week.

22 Jan 2014

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Pandemrix is an influenza vaccination, created in 2009 to combat H1N1, known as Swine Flu. Now, a team of Swedish clinicians testing the vaccine for links to immune-related or neurological diseases have linked Pandemrix to an increased risk of narcolepsy in young adults.

21 Jan 2014

Study provides insight into physician recommendations to improve HPV vaccination

The risk of developing cervical cancer can be significantly decreased through human papillomavirus vaccination. Despite calls from leading health and professional organizations for universal vaccination for girls ages 11 and 12, the most recently published national data indicate that only 14.5 percent of 11- and 12-year-old girls have received at least one dose of the HPV vaccine and 3 percent have completed the three-dose series. A new Moffitt Cancer Center study provides insight into physician recommendations, one important factor that may contribute to these low levels of uptake.

21 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

First Edition: January 21, 2014

Today's headlines include news on the health law's implementation at both the federal and state levels.

21 Jan 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

20 Jan 2014

Going barefoot contributes to hookworm infections

Going barefoot in parts of Africa, Asia and South America contributes to hookworm infections, which afflict an estimated 700 million of the world's poor. The parasitic worm lives in the soil and enters the body through the feet. By feeding on victims' blood, the worms cause anemia and, in children, stunted growth and learning problems.

20 Jan 2014

Research provides important new information about transmission of human leishmaniasis

Research involving scientists at the University of York has provided important new information about transmission of human leishmaniasis, a group of infectious diseases which kills more than 100,000 people a year.

18 Jan 2014

Patient's EMR coupled with pharmacist intervention improves preventative care of shingles

While people over the age of 60 account for more than half of all shingles cases, less than 15% get the vaccination that helps prevent the blistering skin rash, which can cause lingering nerve pain.

17 Jan 2014

Kansas State University's research shows promise to fight novel avian H7N9 influenza virus

The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths in China. New research, conducted under the supervision of Kansas State University's Juergen Richt, is showing promise in helping to fight this deadly virus.

17 Jan 2014

Three new spin-offs emerged from Helmholtz Zentrum München

Three new spin-offs emerged from Helmholtz Zentrum München (HMGU) in 2013: SurgVision, Trianta Immunotherapies and Dosimetrics. Thanks to successful innovation management, the Center has transformed excellent research findings into practical applications and given new impulses to the areas of clinical imaging, immunotherapy and radiation dosimetry.

17 Jan 2014

New research shows promise in helping combat novel drug-resistant H7N9 influenza virus

16 Jan 2014

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding.

16 Jan 2014

Scientists develop new nasal vaccine that proves effective against whooping cough

Scientists involved in the EU-funded project ChildInnovac are about to publish in the online journal Plos One the results of their first clinical trial of a new nasal vaccine.

16 Jan 2014

Researchers explore new strategy to defeat drug-resistant strains of malaria

Malaria is one of the most deadly infectious diseases in the world today, claiming the lives of over half a million people every year, and the recent emergence of parasites resistant to current treatments threatens to undermine efforts to control the disease. Researchers are now onto a new strategy to defeat drug-resistant strains of the parasite. Their report appears in the journal ACS Chemical Biology.

15 Jan 2014

Vaccine News and Research

Latest Vaccine News and Research

CWRU researchers receive NIAID grant to conduct HIV research and clinical trials

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

NPS MedicineWise urges parents to ensure that children's vaccinations are up to date

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Study provides insight into physician recommendations to improve HPV vaccination

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

First Edition: January 21, 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

Going barefoot contributes to hookworm infections

Research provides important new information about transmission of human leishmaniasis

Patient's EMR coupled with pharmacist intervention improves preventative care of shingles

Kansas State University's research shows promise to fight novel avian H7N9 influenza virus

Three new spin-offs emerged from Helmholtz Zentrum München

New research shows promise in helping combat novel drug-resistant H7N9 influenza virus

Prostate cancer vaccines receive a boost in funding

Scientists develop new nasal vaccine that proves effective against whooping cough

Researchers explore new strategy to defeat drug-resistant strains of malaria

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in